{"hands_on_practices": [{"introduction": "Clinical decision-making rarely involves a single, perfect choice. This exercise [@problem_id:4887185] challenges you to navigate a realistic scenario where the principles of non-maleficence (do no harm) and beneficence (do good) are in direct tension. By weighing the quantified risks of different treatment options, you will practice the art of risk-benefit analysis, which is central to ethical medical practice, and see how autonomy and justice also guide the optimal course of action.", "problem": "A 67-year-old man requires urgent open cholecystectomy for acute cholecystitis. Surgery is recommended within 4 hours to avoid clinical deterioration. Evidence-based surgical prophylaxis guidelines recommend cefazolin as a first-line antibiotic to reduce surgical site infection. He reports a childhood history of hives after an unknown penicillin; there is no history of anaphylaxis, airway compromise, or hypotension. Formal penicillin skin testing is not immediately available. Observational data for this procedure indicate that without prophylaxis the surgical site infection risk is approximately $5\\%$, whereas with cefazolin prophylaxis it is approximately $1\\%$. The estimated risk of anaphylaxis to cefazolin in patients with non-anaphylactic penicillin allergy is approximately $0.02\\%$. An alternative regimen with clindamycin plus gentamicin reduces infection risk to approximately $2\\%$ but carries risks that include *Clostridioides difficile* infection (CDI) at approximately $1\\%$ and nephrotoxicity at approximately $0.5\\%$. Resuscitation equipment and trained staff are available in the operating suite.\n\nFrom the standpoint of the four biomedical principles—respect for autonomy, beneficence, non-maleficence, and justice—determine whether non-maleficence permits administration of prophylactic antibiotics in this scenario and, if so, what specific documentation best records the harm-avoidance reasoning for the chosen course. Select the single best option.\n\nA. Withhold all prophylactic antibiotics because any nonzero risk of anaphylaxis violates non-maleficence. Document only that antibiotics were not given to avoid potential harm, without quantifying risks or discussing alternatives.\n\nB. Administer cefazolin solely because it is the standard of care. Do not discuss risks or alternatives with the patient. Document only that beneficence overrides non-maleficence and cite guidelines as the sufficient justification.\n\nC. Administer clindamycin plus gentamicin because they avoid beta-lactams, which eliminates immediate allergy risk. Document that non-maleficence requires choosing the option with the lowest immediate allergy risk and omit discussion of other risks or differences in infection prevention.\n\nD. Administer cefazolin after verifying no history of anaphylaxis, provide a concise explanation of comparative quantified risks and benefits (for example, approximately $0.02\\%$ anaphylaxis risk versus approximately 4 percentage points absolute infection risk reduction), prepare mitigation (readiness for airway management and epinephrine; consider a graded test dose if feasible), and obtain informed consent. Document a structured risk-benefit analysis that (i) records the allergy history; (ii) compares expected harms and benefits across cefazolin and alternatives (including CDI and nephrotoxicity risks and infection prevention differences); (iii) lists mitigation measures taken; (iv) notes the patient’s informed consent reflecting respect for autonomy; and (v) explains that the choice follows evidence-based standard-of-care to promote justice.\n\nE. Delay surgery for 24 hours to obtain formal allergy testing to eliminate uncertainty. Document that non-maleficence forbids acting under uncertainty and that avoidance of any foreseeable harm takes precedence over all other considerations.", "solution": "The problem statement is valid. It presents a realistic clinical scenario grounded in established medical facts and quantitative risk data, posing a well-defined question about applying biomedical ethical principles to a decision under uncertainty. The problem is self-contained, internally consistent, and objective.\n\nThe core of this problem lies in the correct application of the four principles of biomedical ethics—autonomy, beneficence, non-maleficence, and justice—to a clinical decision involving competing risks. The question asks specifically whether non-maleficence permits antibiotic administration and which documentation best reflects the harm-avoidance reasoning.\n\nFirst, let us analyze the principle of non-maleficence (\"do no harm\"). This principle is not an absolute prohibition against any action that carries risk. Nearly all medical interventions, including inaction, involve some risk of harm. Therefore, non-maleficence is operationalized through a careful risk-benefit analysis. A course of action is consistent with non-maleficence if the expected benefits outweigh the expected harms, and the chosen action has a more favorable harm-benefit profile compared to all reasonable alternatives.\n\nLet us quantitatively compare the risks and benefits of the available courses of action:\n\n1.  **No Prophylactic Antibiotics:**\n    *   Harm: The risk of surgical site infection (SSI) is given as approximately $5\\%$. An SSI is a significant harm, potentially leading to increased morbidity, prolonged hospitalization, sepsis, and even mortality.\n    *   Benefit: Avoidance of all antibiotic-related adverse effects.\n\n2.  **Prophylaxis with Cefazolin:**\n    *   Harm: The risk of anaphylaxis in this patient with a non-anaphylactic penicillin allergy history is estimated at approximately $0.02\\%$. Anaphylaxis is a severe, life-threatening allergic reaction. However, the problem states that mitigation measures (resuscitation equipment and trained staff) are available, reducing the risk of a fatal outcome.\n    *   Benefit: The SSI risk is reduced to approximately $1\\%$. This represents an absolute risk reduction (ARR) of $5\\% - 1\\% = 4$ percentage points compared to no prophylaxis. This is a substantial benefit.\n\n3.  **Prophylaxis with Clindamycin plus Gentamicin:**\n    *   Harm: This regimen carries a risk of *Clostridioides difficile* infection (CDI) of approximately $1\\%$ and a risk of nephrotoxicity of approximately $0.5\\%$. The sum of these significant potential harms is approximately $1.5\\%$. This regimen entirely avoids the specific risk of beta-lactam allergy but introduces other, more probable, harms.\n    *   Benefit: The SSI risk is reduced to approximately $2\\%$. This represents an ARR of $5\\% - 2\\% = 3$ percentage points compared to no prophylaxis. This is beneficial, but less so than cefazolin.\n\nFrom the standpoint of non-maleficence and beneficence (acting in the patient's best interest), we must compare the net outcomes.\n-   Withholding antibiotics exposes the patient to a $5\\%$ risk of SSI, which is a common and serious harm. Averting this preventable harm is a primary goal.\n-   The clindamycin/gentamicin regimen has a combined risk of significant harm ($\\approx 1.5\\%$) that is approximately $75$ times greater than the risk of anaphylaxis with cefazolin ($\\approx 0.02\\%$). Furthermore, it is less effective at preventing the primary harm of concern (SSI ARR of $3\\%$ vs. $4\\%$).\n-   The cefazolin regimen offers the greatest benefit (highest SSI risk reduction) while posing the smallest risk of a severe adverse drug event ($\\approx 0.02\\%$), especially given that the potential harm of anaphylaxis can be actively mitigated.\n\nTherefore, a rigorous application of non-maleficence and beneficence concludes that administering cefazolin presents the most favorable risk-benefit profile. Non-maleficence does not forbid this action; rather, in concert with beneficence, it compels the clinician to choose the path that maximizes benefit and minimizes net harm.\n\nThe two other principles must also be considered:\n-   **Respect for Autonomy:** The patient must be a partner in this decision. The clinician has the duty to explain the options, including the quantified risks and benefits of each, and the rationale for the recommendation. The patient's informed consent is ethically required before proceeding.\n-   **Justice:** Cefazolin is the evidence-based, first-line standard of care. Adhering to this standard promotes justice by ensuring the patient receives the most effective proven therapy, consistent with what other patients in similar situations would receive.\n\nNow, we evaluate each option:\n\n**A. Withhold all prophylactic antibiotics because any nonzero risk of anaphylaxis violates non-maleficence. Document only that antibiotics were not given to avoid potential harm, without quantifying risks or discussing alternatives.**\nThis option misinterprets non-maleficence as an absolute prohibition of any risk, however small. This perspective is clinically untenable and ethically flawed, as it ignores the greater harm of inaction (the $\\approx 5\\%$ SSI risk). Omitting antibiotics to avoid a $\\approx 0.02\\%$ risk while accepting a $\\approx 5\\%$ risk is a net-harmful decision, thus violating both non-maleficence and beneficence. The proposed documentation is inadequate and non-transparent. **Incorrect.**\n\n**B. Administer cefazolin solely because it is the standard of care. Do not discuss risks or alternatives with the patient. Document only that beneficence overrides non-maleficence and cite guidelines as the sufficient justification.**\nThis option reaches the correct clinical action but for the wrong reasons and via an unethical process. It completely violates the principle of patient autonomy by excluding the patient from the decision-making process. The justification pits beneficence against non-maleficence, which is a false dichotomy; a proper analysis shows that the chosen action serves both principles. Medical paternalism of this kind is ethically unacceptable. **Incorrect.**\n\n**C. Administer clindamycin plus gentamicin because they avoid beta-lactams, which eliminates immediate allergy risk. Document that non-maleficence requires choosing the option with the lowest immediate allergy risk and omit discussion of other risks or differences in infection prevention.**\nThis option exhibits a flawed application of non-maleficence by focusing narrowly on one specific risk (beta-lactam allergy) while ignoring the greater cumulative risk of the alternative ($\\approx 1.5\\%$ risk of CDI/nephrotoxicity) and its inferior efficacy. A comprehensive harm-avoidance strategy must consider all potential harms. The proposed documentation is misleading by omission. **Incorrect.**\n\n**D. Administer cefazolin after verifying no history of anaphylaxis, provide a concise explanation of comparative quantified risks and benefits (for example, approximately $0.02\\%$ anaphylaxis risk versus approximately 4 percentage points absolute infection risk reduction), prepare mitigation (readiness for airway management and epinephrine; consider a graded test dose if feasible), and obtain informed consent. Document a structured risk-benefit analysis that (i) records the allergy history; (ii) compares expected harms and benefits across cefazolin and alternatives (including CDI and nephrotoxicity risks and infection prevention differences); (iii) lists mitigation measures taken; (iv) notes the patient’s informed consent reflecting respect for autonomy; and (v) explains that the choice follows evidence-based standard-of-care to promote justice.**\nThis option provides a comprehensive and ethically robust course of action. It correctly identifies cefazolin as the optimal choice based on a sophisticated risk-benefit analysis (non-maleficence and beneficence). It correctly emphasizes harm mitigation. Crucially, it incorporates respect for autonomy through a detailed informed consent process. It references the standard of care, satisfying the principle of justice. The proposed documentation is exemplary, providing a transparent and defensible record of the clinical and ethical reasoning. This option correctly answers both parts of the question: that non-maleficence permits the action and how the harm-avoidance reasoning should be documented. **Correct.**\n\n**E. Delay surgery for 24 hours to obtain formal allergy testing to eliminate uncertainty. Document that non-maleficence forbids acting under uncertainty and that avoidance of any foreseeable harm takes precedence over all other considerations.**\nThis option introduces a significant new harm. The problem states the surgery is urgent and recommended within 4 hours to avoid clinical deterioration. Delaying surgery for 24 hours risks progression of acute cholecystitis to a more severe state, such as perforation or gangrene, a risk that is almost certainly greater than the $\\approx 0.02\\%$ risk of anaphylaxis. The philosophy that non-maleficence forbids acting under uncertainty is false; clinical medicine is fundamentally about making reasoned decisions in the face of uncertainty. **Incorrect.**", "answer": "$$\\boxed{D}$$", "id": "4887185"}, {"introduction": "To truly respect patient autonomy, we must understand and incorporate their unique values and aversion to risk. This practice [@problem_id:4887214] introduces you to expected utility theory, a powerful tool for translating abstract ethical principles into a concrete, mathematical framework. You will learn how to model a patient's preferences and risk aversion quantitatively, demonstrating how beneficence and non-maleficence can be balanced in a way that is tailored to the individual.", "problem": "A clinician and patient are engaged in shared decision-making about a therapy for a serious condition. The ethical analysis must integrate the four biomedical principles: respect for autonomy, beneficence, non-maleficence, and justice. Use expected utility theory as the decision-theoretic foundation and explicitly tie each ethical principle to components of the calculation.\n\nFundamental bases for the derivation:\n- Respect for autonomy: patient values and risk attitudes should determine the utility function over health outcomes, rather than imposing external preferences.\n- Beneficence and non-maleficence: expected utility aggregates the probabilities and utilities of benefit and harm, embodying net welfare as a weighted sum of outcomes.\n- Justice: assume resource use is neutral for this single-patient decision (no distributional penalty), so no opportunity-cost term is added to the utility; in multi-patient contexts, a fairness term would be introduced, but here it is set to zero.\n- Expected utility theory: for outcomes $x_i$ with probabilities $p_i$ and utility function $u(x)$, the expected utility is $\\sum_i p_i u(x_i)$; choose the option with the larger expected utility.\n\nScenario and data:\n- Initiating therapy yields three mutually exclusive outcomes: with probability $0.6$, a substantial benefit of $+10$ utility; with probability $0.2$, a moderate harm of $-5$ utility; with probability $0.2$, no meaningful change of $0$ utility. The status quo (not initiating therapy) yields $0$ utility.\n- Under risk-neutral evaluation, take $u(x)=x$.\n- To incorporate patient risk aversion consistent with respect for autonomy, use a concave exponential utility $u(x)=1-\\exp(-\\rho x)$, with risk-aversion coefficient $\\rho > 0$, anchored so that $u(0)=0$.\n\nTasks:\n1. Compute the risk-neutral expected utility difference between initiating therapy and not initiating therapy.\n2. Derive a closed-form symbolic expression for the expected utility difference between initiating therapy and not initiating therapy under the exponential utility $u(x)=1-\\exp(-\\rho x)$, as a function of $\\rho$.\n\nProvide both results as your final answer. No rounding is required. Utilities are dimensionless, so do not include any units in your final answer.", "solution": "The problem statement is subjected to validation.\n\n### Step 1: Extract Givens\n- **Ethical Principles and their Decision-Theoretic Mapping:**\n    - Respect for autonomy: Patient values determine the utility function $u(x)$.\n    - Beneficence and non-maleficence: Aggregated into net welfare via expected utility.\n    - Justice: Resource use is neutral for this decision, so no cost term is added to the utility.\n- **Decision Theory Framework:**\n    - Expected utility of a choice is given by $EU = \\sum_i p_i u(x_i)$, where $x_i$ are outcomes, $p_i$ are their probabilities, and $u(x)$ is the utility function.\n- **Scenario Data for Initiating Therapy:**\n    - Outcome 1: $x_1 = +10$ (substantial benefit) with probability $p_1 = 0.6$.\n    - Outcome 2: $x_2 = -5$ (moderate harm) with probability $p_2 = 0.2$.\n    - Outcome 3: $x_3 = 0$ (no change) with probability $p_3 = 0.2$.\n- **Scenario Data for Not Initiating Therapy (Status Quo):**\n    - The status quo yields a utility of $0$.\n- **Utility Functions:**\n    - Risk-neutral evaluation: $u(x) = x$.\n    - Risk-averse evaluation (respecting autonomy): $u(x) = 1 - \\exp(-\\rho x)$ with risk-aversion coefficient $\\rho > 0$, anchored at $u(0) = 0$.\n- **Tasks:**\n    1. Compute the risk-neutral expected utility difference between initiating therapy and the status quo.\n    2. Derive a closed-form symbolic expression for the expected utility difference for the risk-averse case as a function of $\\rho$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the validation criteria.\n- **Scientifically Grounded:** The problem is based on expected utility theory, a cornerstone of decision theory, and its application to medical ethics is a standard, well-established interdisciplinary approach. The utility functions provided, linear for risk neutrality and exponential for constant absolute risk aversion, are canonical forms. The framework is logically and mathematically sound.\n- **Well-Posed:** The problem is clearly defined. All necessary data (probabilities, outcome values, utility functions) are provided to perform the required calculations. The questions are unambiguous and lead to unique, verifiable solutions.\n- **Objective:** The problem is stated in precise, quantitative terms. The mapping of qualitative ethical principles to specific components of the mathematical model is explicitly given, avoiding subjective interpretation.\n\n### Step 3: Verdict and Action\nThe problem is valid. It is scientifically sound, well-posed, and objective. A solution will be derived.\n\nThe solution proceeds by addressing the two tasks as specified.\n\n**Task 1: Risk-Neutral Expected Utility Difference**\n\nFirst, we calculate the expected utility of initiating therapy, denoted as $EU_{therapy}$, under the risk-neutral utility function $u(x) = x$. The expected utility is the sum of the utilities of each outcome weighted by their respective probabilities.\nThe outcomes and probabilities are given as:\n$x_1 = 10$ with $p_1 = 0.6$\n$x_2 = -5$ with $p_2 = 0.2$\n$x_3 = 0$ with $p_3 = 0.2$\n\nThe expected utility formula is:\n$$EU = \\sum_{i=1}^{3} p_i u(x_i) = p_1 u(x_1) + p_2 u(x_2) + p_3 u(x_3)$$\nSubstituting the risk-neutral utility function $u(x)=x$:\n$$EU_{therapy} = p_1 x_1 + p_2 x_2 + p_3 x_3$$\nPlugging in the given values:\n$$EU_{therapy} = (0.6)(10) + (0.2)(-5) + (0.2)(0)$$\n$$EU_{therapy} = 6 - 1 + 0 = 5$$\nThe utility of the status quo (not initiating therapy) is given as $EU_{status\\_quo} = 0$.\nThe expected utility difference, $\\Delta EU$, is the difference between the expected utility of therapy and the status quo:\n$$\\Delta EU_{neutral} = EU_{therapy} - EU_{status\\_quo} = 5 - 0 = 5$$\n\n**Task 2: Risk-Averse Expected Utility Difference**\n\nNext, we derive a symbolic expression for the expected utility difference using the concave exponential utility function $u(x) = 1 - \\exp(-\\rho x)$, which reflects patient-specific risk aversion (respect for autonomy).\nThe anchor condition $u(0) = 1 - \\exp(-\\rho \\cdot 0) = 1 - \\exp(0) = 1 - 1 = 0$ is satisfied.\n\nWe calculate the expected utility of therapy, $EU_{therapy}(\\rho)$, using this utility function.\n$$EU_{therapy}(\\rho) = p_1 u(x_1) + p_2 u(x_2) + p_3 u(x_3)$$\nThe utilities for each outcome are:\n$u(x_1) = u(10) = 1 - \\exp(-10\\rho)$\n$u(x_2) = u(-5) = 1 - \\exp(-(-5)\\rho) = 1 - \\exp(5\\rho)$\n$u(x_3) = u(0) = 0$\n\nSubstituting these into the expected utility formula:\n$$EU_{therapy}(\\rho) = (0.6)(1 - \\exp(-10\\rho)) + (0.2)(1 - \\exp(5\\rho)) + (0.2)(0)$$\nExpanding the expression:\n$$EU_{therapy}(\\rho) = 0.6 - 0.6\\exp(-10\\rho) + 0.2 - 0.2\\exp(5\\rho)$$\nCombining the constant terms:\n$$EU_{therapy}(\\rho) = 0.8 - 0.6\\exp(-10\\rho) - 0.2\\exp(5\\rho)$$\nThe utility of the status quo is $u(0) = 0$, so $EU_{status\\_quo}(\\rho) = 0$.\nThe expected utility difference, $\\Delta EU(\\rho)$, as a function of the risk-aversion coefficient $\\rho$, is:\n$$\\Delta EU(\\rho) = EU_{therapy}(\\rho) - EU_{status\\_quo}(\\rho)$$\n$$\\Delta EU(\\rho) = (0.8 - 0.6\\exp(-10\\rho) - 0.2\\exp(5\\rho)) - 0$$\n$$\\Delta EU(\\rho) = 0.8 - 0.6\\exp(-10\\rho) - 0.2\\exp(5\\rho)$$\nThis is the closed-form symbolic expression for the expected utility difference for a risk-averse patient.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n5 & 0.8 - 0.6\\exp(-10\\rho) - 0.2\\exp(5\\rho)\n\\end{pmatrix}\n}\n$$", "id": "4887214"}, {"introduction": "When healthcare resources are scarce, who should receive them? This hands-on practice [@problem_id:4887193] places you on a triage committee to confront the classic ethical tension between beneficence and justice. Using the concept of Quality-Adjusted Life Years (QALYs), you will explore how a purely utilitarian approach of maximizing total health can conflict with our intuitive desire to prioritize the worse-off, and learn to quantify the strength of this commitment to justice through a priority weight $w$.", "problem": "A hospital triage committee must allocate a single available treatment slot to exactly $1$ of $3$ patients, labeled $A$, $B$, and $C$. All treatments have equal cost, all patients are competent and give informed consent, and the treatments pose no material risk beyond standard care. If patient $i \\in \\{A,B,C\\}$ is treated, the expected benefit is an additional $q_i$ Quality-Adjusted Life Years (QALYs), where Quality-Adjusted Life Year (QALY) is a commonly used measure of health benefit that weights life-years by health-related quality. The expected QALY gains are: $q_A = 2$, $q_B = 1.5$, and $q_C = 0.8$.\n\nFrom the perspective of the four biomedical principles—respect for autonomy, beneficence, non-maleficence, and justice—the committee first considers the unweighted beneficence-oriented rule that selects the treatment option that maximizes expected total QALYs. Next, to incorporate justice as priority to the worse-off, the committee models distributive priority by a multiplicative weight $w \\geq 1$ applied only to the uniquely worse-off patient $C$, leaving the others unweighted. That is, the justice-weighted social value of treating patient $i$ is $v_i = w_i q_i$, where $w_A = 1$, $w_B = 1$, and $w_C = w$. The allocation rule is to select the patient with the highest $v_i$.\n\nTasks:\n- Using only the definitions above, determine the minimal priority weight $w^{\\ast}$ such that the justice-weighted rule would select treating patient $C$ rather than either $A$ or $B$ under the single-slot budget. Express $w^{\\ast}$ as an exact number with no units.\n- In your reasoning (to be shown in your solution), ground your analysis in the four principles by explaining why unweighted QALY maximization aligns with beneficence yet may conflict with justice when one patient is worse off, and how the threshold $w^{\\ast}$ encodes the strength of justice-based priority required to override pure QALY maximization.\n\nProvide your final numeric answer for $w^{\\ast}$ as an exact number with no units. No rounding is required.", "solution": "The problem presents a formal model for resource allocation in a medical context, balancing the principles of beneficence and justice. We are asked to determine a specific threshold within this model and to ground the analysis in the four fundamental principles of biomedical ethics.\n\nFirst, we validate the problem statement. The givens are:\n-   Three patients, $\\{A, B, C\\}$, competing for a single treatment slot.\n-   Expected Quality-Adjusted Life Year (QALY) gains are $q_A = 2$, $q_B = 1.5$, and $q_C = 0.8$.\n-   Patient $C$ is identified as the \"uniquely worse-off\" patient.\n-   The justice-weighted social value of treating patient $i$ is $v_i = w_i q_i$.\n-   The weights are $w_A = 1$, $w_B = 1$, and $w_C = w$, with the constraint that $w \\geq 1$.\n-   The allocation rule is to select the patient with the highest value of $v_i$.\n\nThe problem is scientifically grounded, using standard concepts from health economics (QALYs) and bioethics (the four principles, prioritarianism). It is well-posed, providing all necessary information to calculate the required threshold, $w^{\\ast}$. The language is objective and the setup is internally consistent. Therefore, the problem is deemed valid and a solution can be formulated.\n\nThe ethical framework involves four principles: autonomy, non-maleficence, beneficence, and justice. The problem states that patients are competent and consent (satisfying autonomy) and that treatments pose no significant risk (satisfying non-maleficence). These two principles are therefore upheld regardless of the allocation choice and do not differentiate between the options. The core of the dilemma lies in the tension between beneficence and justice.\n\nThe principle of beneficence, or acting to provide benefit, is represented by the unweighted QALY maximization rule. This utilitarian approach aims to produce the greatest aggregate health good from the available resource. Under this rule, the choice would be to treat the patient for whom the expected QALY gain is maximal. Comparing the given values:\n$$q_A = 2$$\n$$q_B = 1.5$$\n$$q_C = 0.8$$\nSince $q_A > q_B > q_C$, a purely beneficence-oriented rule would select patient $A$. This maximizes the total health gain produced by the single treatment slot.\n\nThe principle of justice, particularly distributive justice, concerns the fair allocation of resources. The problem introduces a prioritarian form of justice, which gives special weight to the well-being of the worse-off. Patient $C$ is designated as the worse-off individual. A pure QALY-maximization approach (beneficence) may conflict with this conception of justice because it directs resources to where they produce the most gain, potentially neglecting those who are already disadvantaged but have a lower capacity to benefit from treatment. This is precisely the case here, as the worse-off patient $C$ is also the one who stands to gain the fewest QALYs.\n\nTo formalize this justice-based priority, a weight $w \\geq 1$ is applied to the QALYs of the worse-off patient, $C$. This creates a new metric, the justice-weighted social value $v_i$. We can calculate these values for each patient:\n$$v_A = w_A q_A = 1 \\cdot 2 = 2$$\n$$v_B = w_B q_B = 1 \\cdot 1.5 = 1.5$$\n$$v_C = w_C q_C = w \\cdot 0.8$$\n\nThe task is to find the minimal priority weight, $w^{\\ast}$, that would lead the committee to select patient $C$. For patient $C$ to be chosen, their justice-weighted value, $v_C$, must be greater than or equal to the values for both patient $A$ and patient $B$. This gives us a system of two inequalities:\n$$v_C \\geq v_A \\implies 0.8 w \\geq 2$$\n$$v_C \\geq v_B \\implies 0.8 w \\geq 1.5$$\n\nWe solve each inequality for $w$:\nFrom the first inequality:\n$$w \\geq \\frac{2}{0.8} = \\frac{20}{8} = \\frac{5}{2} = 2.5$$\nFrom the second inequality:\n$$w \\geq \\frac{1.5}{0.8} = \\frac{15}{8} = 1.875$$\n\nFor patient $C$ to be selected over *both* other patients, both conditions must be satisfied. Therefore, $w$ must be greater than or equal to the maximum of the two lower bounds:\n$$w \\geq \\max(2.5, 1.875)$$\n$$w \\geq 2.5$$\n\nThe minimal value of $w$ that satisfies this condition is $w^{\\ast} = 2.5$.\n\nThis threshold $w^{\\ast} = 2.5$ quantifies the strength of the justice-based priority required to override the decision based on pure beneficence (QALY maximization). It signifies that the committee must value each QALY gained by the worse-off patient, $C$, as being $2.5$ times more valuable than a QALY gained by any other patient. If the committee's ethical commitment to prioritizing the worse-off is weaker than this (i.e., if they choose a weight $w < 2.5$), the principle of beneficence would still dominate, and patient $A$ would be treated. At the precise threshold of $w = 2.5$, the justice-weighted value for patient $C$ ($v_C = 2.5 \\cdot 0.8 = 2$) becomes equal to the value for patient $A$, making them equally preferable under the weighted rule. For any $w > 2.5$, patient $C$ becomes the strictly preferred choice. Thus, $w^{\\ast} = 2.5$ is the inflection point where the demand of justice, as formalized in this model, becomes decisive.", "answer": "$$\\boxed{\\frac{5}{2}}$$", "id": "4887193"}]}